Evidence map›Paper›PMID 30796732›Full record

ReviewWorld journal of pediatrics : WJP2020

Immunological pathogenesis and treatment of systemic lupus erythematosus.

Lu Pan, Mei-Ping Lu, Jing-Hua Wang, Meng Xu, Si-Rui Yang

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of pediatrics : WJP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
230citing papers in PubMed, 9 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

230 citing papers in PubMed, 9 syntheses or guidelines pooled it, 389 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Effects ofNarra J · 2024
    Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

170 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lu PanDepartment of Pediatric Rheumatology and Allergy, The First Hospital, Jilin University, Changchun, China.
Mei-Ping LuDepartment of Allergy Immunology and Rheumatology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jing-Hua WangDepartment of Pediatric Rheumatology and Allergy, The First Hospital, Jilin University, Changchun, China.
Meng XuDepartment of Pediatric Rheumatology and Allergy, The First Hospital, Jilin University, Changchun, China.
Si-Rui YangDepartment of Pediatric Rheumatology and Allergy, The First Hospital, Jilin University, Changchun, China. sryang@jlu.edu.cn.ORCID http://orcid.org/0000-0001-7984-3569
Jilin University · CNChildren's Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic lupus erythematosis (SLE) is a complex and clinically heterogeneous autoimmune disease. A variety of immunological defects contribute to SLE, including dysregulated innate and adaptive immune response. A clearer understanding of the mechanisms driving disease pathogenesis combined with recent advances in medical science is predicted to enable accelerated progress towards improved SLE-personalized approaches to treatment. The aim of this review was to clarify the immunological pathogenesis and treatment of SLE. DATA SOURCES: Literature reviews and original research articles were collected from database, including PubMed and Wanfang. Relevant articles about SLE were included.

resultsBreakdown of self-tolerance is the main pathogenesis of SLE. The innate and adaptive immune networks are interlinked with each other through cytokines, complements, immune complexes and kinases of the intracellular machinery. Treatments targeted at possible targets of immunity have been assessed in clinical trials. Most of them did not show better safety and efficacy than traditional treatments. However, novel targeting treatments are still being explored.

conclusionsDysregulated immune response plays a critical role in SLE, including innate immunity and adaptive immunity. Biologic agents that aim to specifically target abnormal immune processes were assessing and may bring new hope to SLE patients.

Indexed as

Adaptive ImmunityAntirheumatic AgentsChildHumansImmunity, InnateImmunosuppressive AgentsLupus Erythematosus, SystemicAntirheumatic AgentsImmunosuppressive AgentsImmunological pathogenesisSystemic lupus erythematosisTreatment

Identifiers

PMID30796732
PMCPMC7040062
OpenAlexW2915615482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.